Animal Study Finds Vitamin D Inhibits Prostate Cancer Growth
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Animal Study Finds Vitamin D Inhibits Prostate Cancer Growth

San Diego -- April 10, 1997 -- Vitamin D significantly inhibits highly metastatic, or widespread, prostate cancer in animals, suggesting that it has important potential for treating men with similar advanced disease.
"This is the first evidence that vitamin D can effectively treat an animal with advanced prostate cancer that spreads to the bone, similar to what happens in men affected with this disease," said Ben Light, M.D., a researcher with the UPCI's Experimental Therapeutics Program who presented these findings April 14 at the annual meeting of the American Association for Cancer Research.

In their study, the UPCI research team implanted highly metastatic prostate tumors into rats and treated them with vitamin D (1,25-dihydroxycholecalciferol). After three weeks of therapy, tumors in treated rats were 88 percent smaller than those in control rats which received tumors but were not treated. In addition, the treated rats had 75 percent fewer lung metastases, and these metastases were 85 percent smaller than those seen in untreated controls.

UPCI scientists were the first to describe vitamin D's anti-cancer effects in this prostate model. Past epidemiologic studies by UPCI investigators and others have shown that old age, black race, and residence in northern latitudes -- known risk factors for prostate cancer -- all correlate with low blood levels of vitamin D.

Recently, they have shown that vitamin D may be involved in the growth and differentiation of the normal prostate. Vitamin D binds to cancer cells and triggers either cancer cell death or the transformation of cancer cells into more benign, less malignant cells.

UPCI clinical investigators are currently incorporating vitamin D in early clinical (human) studies for advanced prostate cancer as well as other tumors.

Other investigators involved in the research include Candace Johnson, Ph.D., Robert Getzenberg, Ph.D., and Donald Trump, M.D.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities